Published in J Cancer Res Clin Oncol on May 17, 2003
Increasing Pneumocystis pneumonia, England, UK, 2000-2010. Emerg Infect Dis (2013) 1.23
Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. Cancer Chemother Pharmacol (2013) 0.90
Pneumocystis jiroveci Pneumonia in an Atypical Host. Clin Breast Cancer (2011) 0.84
Pneumocystis jiroveci prophylaxis in patients undergoing Bendamustine treatment: the need for a standardized protocol. Clin Case Rep (2015) 0.75
Pneumocystis pneumonia during Postoperative Adjuvant Chemotherapy for Breast Cancer. Case Rep Oncol Med (2013) 0.75
A case of Pneumocystis jiroveci pneumonia after bendamustine-based chemotherapy for refractory diffuse large B-cell lymphoma. Blood Res (2016) 0.75
Unsuspected Pneumocystis pneumonia in an HIV-seronegative patient with untreated lung cancer: circa case report. J Med Case Rep (2007) 0.75
Routine use of bendamustine and rituximab combination therapy in consecutive patients with lymphoproliferative diseases: a survey from Tyrolean hospitals. Wien Klin Wochenschr (2011) 0.75
The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med (1990) 4.25
Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs (1996) 1.56
Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol (2001) 1.12
Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study. J Cancer Res Clin Oncol (1998) 0.98
Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours. Ann Oncol (2000) 0.91
Repeated administration of short infusions of bendamustine: a phase I study in patients with advanced progressive solid tumours. J Cancer Res Clin Oncol (2000) 0.90
Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol (1993) 0.88
Pneumocystis carinii pneumonia as a complication of immunosuppressive therapy. Infection (2000) 0.87
Reversed helper/suppressor T-lymphocyte ratio in bronchoalveolar lavage fluid from patients with breast cancer and Pneumocystis carinii pneumonia. Am Rev Respir Dis (1991) 0.84
Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment. Leuk Lymphoma (1999) 0.83
[Palliative radiochemotherapy with Bendamustin for advanced recurrent head and neck tumors]. Strahlenther Onkol (2001) 0.77
Pneumocystis carinii pneumonia associated with weekly methotrexate: cumulative dose of methotrexate and low CD4 cell count may predict this complication. Respir Med (1993) 0.75
[Bendamustine, vincristine, prednisolone (BOP) in therapy of advanced low-grade non-Hodgkin lymphoma]]. Dtsch Med Wochenschr (2001) 0.75
[Therapeutic results and toxic side effects of the combination cytostasan, adriamycin and vincristine as second-line therapy of metastatic breast cancer]. Arch Geschwulstforsch (1989) 0.75
Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet (1994) 3.24
Current treatment options in dermatofibrosarcoma protuberans. J Cancer Res Clin Oncol (2009) 2.11
Prognosis and treatment of disseminated uveal melanoma. Cancer (1993) 1.98
Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin Cancer Res (2001) 1.91
Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol (2003) 1.86
Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol (1998) 1.77
Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia (2004) 1.45
[Mobilization of stem cells by granulocyte colony-stimulating factor for the regeneration of myocardial tissue after myocardial infarction]. Dtsch Med Wochenschr (2004) 1.42
A phase II study of weekly high-dose 5-fluorouracil and leucovorin plus biweekly alternating doxorubicin and cisplatin for advanced gastric carcinoma. J Cancer Res Clin Oncol (1998) 1.42
Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant (2003) 1.31
Breast cancer patients' expectations in respect of the physician-patient relationship and treatment management results of a survey of 617 patients. Ann Oncol (2007) 1.16
Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol (2001) 1.12
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia (2003) 1.11
Gastric cancer in very young adults: apropos four patients and a review of the literature. J Cancer Res Clin Oncol (2000) 1.11
Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol (2002) 1.11
Commitment to differentiation of human promyelocytic leukemia cells (HL60): an all-or-none event preceded by reversible losses of self-renewal potential. J Cell Physiol (1985) 1.04
Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol (2003) 1.03
Molecular characterization of breast cancer cell lines by expression profiling. J Cancer Res Clin Oncol (2002) 1.00
Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine. J Cancer Res Clin Oncol (2001) 0.99
Differential interaction of magnetic nanoparticles with tumor cells and peripheral blood cells. J Cancer Res Clin Oncol (2006) 0.97
Circulating immune complexes in rats bearing chemically induced tumours. II. Characterization of sera from different stages of tumour growth. Int J Cancer (1978) 0.97
Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. Leukemia (2002) 0.96
[Chemotherapy of malignant bone tumors]. Chirurg (1977) 0.95
Rapid screening and sensitive detection of NPM1 (nucleophosmin) exon 12 mutations in acute myeloid leukaemia. Leuk Res (2007) 0.95
Letter: Chromosome abnormalities in angioimmunoblastic lymphadenopathy. Lancet (1976) 0.93
Expression, regulation and clinical significance of bone morphogenetic protein 6 in esophageal squamous-cell carcinoma. Int J Cancer (1999) 0.93
Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood (1990) 0.92
Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors. Bone Marrow Transplant (2004) 0.91
[Cardiac manifestations of peripheral primitive neuroectodermal tumor (pPNET): a rare case]. Dtsch Med Wochenschr (2000) 0.91
Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group. Br J Cancer (2002) 0.88
Bone morphogenetic protein 2 (BMP-2) induces sequential changes of Id gene expression in the breast cancer cell line MCF-7. J Cancer Res Clin Oncol (2000) 0.88
Severe non-haematological toxicity after treatment with gemcitabine. J Cancer Res Clin Oncol (1999) 0.88
Resistance of macrophages to the suppressive effect of interleukin-10 following thermal injury. Am J Physiol Cell Physiol (2001) 0.87
Expression of bone morphogenetic protein 6 in normal mammary tissue and breast cancer cell lines and its regulation by epidermal growth factor. Int J Cancer (1999) 0.87
Circulating immune complexes in rats bearing chemically induced tumors. I. Sequential determination during the growth of tumours at various body sites. Int J Cancer (1978) 0.87
Acute abdomen by varicella zoster virus induced gastritis after autologous peripheral blood stem cell transplantation in a patient with non-Hodgkin's lymphoma. Acta Haematol (2006) 0.86
Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor. Ann Hematol (1999) 0.86
Rat Clq: similarity to human Clq in functional and compositional properties. Immunochemistry (1978) 0.86
Impact of early NK cell recovery on development of GvHD and CMV reactivation in dose-reduced regimen prior to allogeneic PBSCT. Bone Marrow Transplant (2005) 0.85
Health-related quality of life in elderly cancer patients, elderly non-cancer patients and an elderly general population. Eur J Cancer Care (Engl) (2009) 0.84
Invasive bronchopulmonary aspergillosis leading to rapidly progressive respiratory failure in a patient with severe aplastic anemia. Klin Wochenschr (1987) 0.84
BRCA1 mutations in German breast-cancer families. Int J Cancer (1996) 0.84
Current treatment options for neuroendocrine tumors. Drugs Today (Barc) (2011) 0.84
The neu-oncogene product in serum and tissue of patients with breast carcinoma. Ann Oncol (1993) 0.84
Isolated brain metastases as the sole manifestation of a late relapse in breast cancer. J Cancer Res Clin Oncol (2001) 0.83
Filgrastim mobilization and collection of allogeneic blood progenitor cells from adult family donors: first interim report of a prospective German multicenter study. Ann Hematol (2002) 0.82
Dissociation and isolation of antigen and antibody from immune complexes. J Immunol Methods (1982) 0.82
Requestioning depression in patients with cancer: contribution of somatic and affective symptoms to Beck's Depression Inventory. Ann Oncol (2007) 0.81
Impaired granulocytic function in patients with acute leukaemia: only partial normalisation after successful remission-inducing treatment. J Cancer Res Clin Oncol (1998) 0.81
Quantification of immune complexes by nephelometry. Methods Enzymol (1981) 0.81
The neu oncogene product in serum and tissue of patients with metastatic gastrointestinal carcinomas. J Cancer Res Clin Oncol (1996) 0.81
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial. Eur J Cancer (2004) 0.80
ATRA can enhance apoptosis that is induced by Flt3 tyrosine kinase inhibition in Flt3-ITD positive cells. Leuk Res (2006) 0.80
A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma. Cancer Immunol Immunother (1989) 0.79
[Significance of multiple organ failure for the prognosis of surgical intensive care patients]. Dtsch Med Wochenschr (2006) 0.79
Tamoxifen treatment before orchiectomy in advanced breast cancer in men. N Engl J Med (1981) 0.78
Flt3-ITD mutations can generate leukaemia specific neoepitopes: potential role for immunotherapeutic approaches. Leuk Lymphoma (2006) 0.78
Quantitation of immune complexes by nephelometry. J Immunol Methods (1979) 0.78
Distinct reconstitution of neutrophil functions after allogeneic peripheral blood stem cell transplantation. J Cancer Res Clin Oncol (2007) 0.78
[Hormone therapy, chemotherapy and immunotherapy in breast carcinoma. The best strategy for your patient]. MMW Fortschr Med (2003) 0.78
The role of apoptosis in hematologic malignancies and modulation of apoptosis as a new therapeutic approach. J Cancer Res Clin Oncol (1999) 0.78
Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors. J Cancer Res Clin Oncol (2002) 0.78
Treatment with granulocyte-colony stimulating factor in patients with acute myocardial infarction. Evidence for a stimulation of neovascularization and improvement of myocardial perfusion. Pharmazie (2006) 0.77
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML). Ann Hematol (2000) 0.77
Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study. Cancer Immunol Immunother (1993) 0.77
Exanthema in Legionnaires' disease mimicking a severe cutaneous drug reaction. Clin Exp Dermatol (2009) 0.77
Immune complexes and prognosis of human breast cancer. Lancet (1978) 0.77
Serum cytokine levels in cancer patients treated with different schedules of ultra-low-dose interleukin-2. J Immunother Emphasis Tumor Immunol (1994) 0.77
Early versus late administration of pegfilgrastim after high-dose chemotherapy and autologous hematopoietic stem cell transplantation. J Cancer Res Clin Oncol (2011) 0.77
Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer. Cancer Chemother Pharmacol (1987) 0.77
Hepatic veno-occlusive disease (VOD) with complete occlusion of liver venules after tandem autologous stem cell transplantation-- successful treatment with high-dose methylprednisolone and defibrotide. J Cancer Res Clin Oncol (2002) 0.77
Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. J Cancer Res Clin Oncol (2002) 0.77
Malignancies in patients with insulin-treated diabetes mellitus. J Cancer Res Clin Oncol (2000) 0.76
Initial treatment of acute graft-versus-host disease with a murine monoclonal antibody directed to the human alpha/beta T cell receptor. Cancer Immunol Immunother (1991) 0.76
BRCA1 mutations and phenotype. J Cancer Res Clin Oncol (1997) 0.76
Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis. Br J Haematol (2001) 0.76
Primary gastric non-Hodgkin's lymphoma: a clinicopathological study of 41 patients. J Cancer Res Clin Oncol (1995) 0.76
Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer. Cancer Treat Rep (1986) 0.76
High-dose medroxyprogesterone acetate in advanced breast cancer. Clinical and pharmacokinetic study with a combined oral and intramuscular regimen. Cancer (1989) 0.76
Circadian variation of dihydropyrimidine dehydrogenase mRNA expression in leukocytes and serum cortisol levels in patients with advanced gastrointestinal carcinomas compared to healthy controls. J Cancer Res Clin Oncol (2001) 0.76
Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients: original analysis of non-hematological toxicity and patient characteristics in a pilot investigation. Int J Clin Pharmacol Ther (2006) 0.76
[Bendamustine, vincristine, prednisolone (BOP) in therapy of advanced low-grade non-Hodgkin lymphoma]]. Dtsch Med Wochenschr (2001) 0.75
Phase II study of high-dose medroxyprogesterone acetate in advanced malignant melanoma. Br J Cancer (1989) 0.75
[Progressive multifocal leukoencephalopathy. Late complication in chronic lymphatic leukemia]. Dtsch Med Wochenschr (1987) 0.75
Depressed T cell-derived IFN-gamma following trauma-hemorrhage: a potential mechanism for diminished APC responses. Langenbecks Arch Surg (2007) 0.75
[Gastrointestinal manifestation of Hodgkin's disease]. Med Welt (1973) 0.75
[Therapy of acute myeloid leukemia in the elderly patient]. Z Gerontol Geriatr (2001) 0.75
[Scintigraphic findings in abdominal manifestation of lymphoreticular systemic diseases]. Med Welt (1973) 0.75
[Treatment of Hodgkin's disease of the stomach]. Dtsch Med Wochenschr (1973) 0.75